An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 13, 2015

Primary Completion Date

December 29, 2017

Study Completion Date

December 29, 2017

Conditions
Colorectal Cancer
Interventions
OTHER

Bevacizumab

Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.

COMBINATION_PRODUCT

Chemotherapy

Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.

Trial Locations (22)

1032

Szent Margit Hospital, Budapest

1083

Semmelweis Egyetem Onkologiai Központ, Budapest

1115

Szent Imre Hospital, Budapest

1122

Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest

1125

Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika, Budapest

1145

Fövárosi Önkormányzat uzsoki utcai Kórház, Budapest

2800

Szent Borbala Korhaz, Tatabánya

3501

Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc

4031

Kenezy Korhaz Rendelointezet, Debrecen

4032

Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen

4400

Josa Andras Korhaz; Dept of Oncoradiology, Nyíregyháza

5703

Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek, Gyula

6000

Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, Kecskemét

6720

Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged

7100

Tolna Megyei Onkormanyzat Balassa Janos Korhaz, Szekszárd

7400

Kaposi Mor Teaching Hospital, Kaposvár

7624

Pécsi Tudományegyetem Áok; Onkoterapias Intezet, Pécs

8000

Szent Gyorgy Korhaz;Fejer Megyei, Székesfehérvár

8200

Veszprem Megyei Csolnoky; Ferenc Korhaz, Veszprém

8900

Zala megyei Önkormányzat Kórház és Rendelõintézet, Zalaegerszeg

9024

Petz Aladar Megyei Oktato Korhaz, Győr

9700

Markusovszky Hospital, Szombathely

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02305615 - An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC) | Biotech Hunter | Biotech Hunter